Stoke Therapeutics, Inc. 4

Chief Medical Officer Barry Ticho sold a total of 7,176 shares of Stoke Therapeutics, Inc. common stock on August 3, 2026 under a Rule 10b5-1 plan, leaving him with 20,422 shares directly owned.

On August 3, 2026, Stoke Therapeutics, Inc. Chief Medical Officer Barry Ticho executed two open-market sales of common stock under a pre-arranged Rule 10b5-1 trading plan. He sold 5,907 shares at a weighted average price of approximately $28.95 per share, for proceeds of roughly $171,000, and an additional 1,269 shares at a weighted average price of approximately $29.45 per share, for proceeds of roughly $37,000. The sales were executed in multiple trades within disclosed price ranges around the reported averages. Following these transactions, Ticho’s direct ownership decreased to 21,691 shares after the first sale and then to 20,422 shares after the second sale, implying a remaining direct stake valued at approximately $591,000 using the latter weighted-average sale price as a proxy for the current share price.

Filing Facts

CIK

1623526

Ticker

STOK

Form

4

Source Type

fda

Accession

0001780088-26-000017

Alert Tier

6